Bleeding patterns of women using Lunelle™ monthly contraceptive injections (medroxyprogesterone acetate and estradiol cypionate injectable suspension) compared with those of women using Ortho-Novum® 7/7/7 (norethindrone/ethinyl estradiol triphasic) or other oral contraceptives

Contraception

Volumn 62, Issue 6, 2000, Pages 289-295

  Garceau, Roger J ^a   Wajszczuk, Charles J ^a   Kaunitz, Andrew M ^b  

^a PFIZER INC   (United States)

^b UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER   (United States)

Author keywords

Breakthrough bleeding; Estradiol cypionate; LUNELLE ; Medroxyprogesterone acetate; Monthly injectable contraception; Oral contraceptive; Ortho Novum 7 7 7; Withdrawal bleeding

Indexed keywords

DESOGESTREL PLUS ETHINYLESTRADIOL; ESTRADIOL CYPIONATE PLUS MEDROXYPROGESTERONE ACETATE; ETHINYLESTRADIOL PLUS GESTODENE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORETHISTERONE; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; INJECTABLE CONTRACEPTIVE AGENT; MESTRANOL PLUS NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; ORTHO 777;

ADULT; AMENORRHEA; ARTICLE; BREAKTHROUGH BLEEDING; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HORMONAL CONTRACEPTION; HUMAN; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; ORAL CONTRACEPTION; OVULATION; PREDICTION;

EID: 0034481004     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(00)00183-9     Document Type: Review

References (26)

1. Trends in contraceptive use in the United States: 1982-1995
2. The essentials of contraception. Efficacy, safety, and personal considerations
3. Contraceptive failure rates based on the 1988 National Survey of Family Growth
4. Contraceptive failure rates: New estimates from the 1995 National Survey of Family Growth
5. Oral contraceptive discontinuation: A prospective evaluation of frequency and reasons
6. The patient's reaction to side effects of oral contraceptives
7. Compliance, counseling, and method satisfaction with oral contraceptives: A prospective evaluation
8. Compliance and oral contraceptives: A review
9. Clinical comparison of triphasic norgestimate/35 micrograms ethinyl estradiol and monophasic norethindrone acetate/20 micrograms ethinyl estradiol. Cycle control, lipid effects, and user satisfaction
10. Oral contraceptive estrogen dose considerations
11. Injectable depot medroxyprogesterone acetate contraception: An update for US clinicians
12. Levonorgestrel capsule implants in the United States: A 5-year study
13. Experiences of injectable contraceptive users in an urban setting
14. A multicenter phase III comparative study of two hormonal contraceptive preparations given once-a-month by intramuscular injection: I. Contraceptive efficacy and side effects
15. New once-a-month injectable contraceptives, with particular reference to Cyclofem®/Cyclo-Provera®
16. Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): A contraceptive method for women in the US and worldwide
17. Comparative safety, efficacy, and cycle control of Lunelle™ monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension) and NET/EE oral contraceptive (norethindrone/ethinyl estradiol triphasic)
18. Menstrual bleeding patterns in untreated women
19. Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): Steady-state pharmacokinetics of medroxyprogesterone acetate and estradiol in surgically sterile women
20. Evaluation of the clinical performance of three triphasic oral contraceptives: A multicenter, randomized, comparative trial
21. Triphasic randomized clinical trial: Comparative frequency of intermenstrual bleeding
22. A comparison of a new graduated estrogen formulation with three constant dose oral contraceptives
23. Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 micrograms levonorgestrel and 20 micrograms ethinyl estradiol (Alesse)
24. A comparison of the cycle control and tolerability of two ultra low-dose oral contraceptives containing 20 μg ethinylestradiol and either 150 μg desogestrel or 75 μg gestodene
25. An open-label, multicenter, noncomparative safety and efficacy study of Mircette™, a low-dose estrogen-progestin oral contraceptive
26. Cycle control on low-dose oral contraceptives: A comparative trial